Michael Hagensee1, Jose A. Vazquez2, Jennifer Cameron1, Elizabeth Lilly1, Paul Fidel 1
Medical College of Georgia, Augusta, GA
Objective: The prevalence of oral HPV 16 and 32 infections werestudied in HIV-infected individuals over the past 19 years in New Orleans. Clinicians and dentists have noted a decrease in the prevalence of oral warts (HPV-32) and few oral cancers (HPV-16) in HIV+ individuals over this time. This may be a long-term impact of anti-retroviral therapy (ART) and its effect on immunity. This analysis combines multiple cross-sectional studies from 2000-2018.
Methods: Saliva, oral gargles or swab samples were collected from cohorts of HIV+ individuals from 2000-04, 2005-09, and 2013-18. Isolated DNA from these samples were tested for HPV-16 and 32 by type-specific PCR assays or the Roche Linear Array. Demographic characteristics were collected as well as HIV viral loads and CD4 cell counts.
Results: The 2000-04 cohort (n=499) demonstrated a prevalence of 4.2% for oral HPV-16 infection and 7.8% for HPV-32 infection. Prevalence was markedly increased in a smaller cohort (n=110) enrolled from 2005-09 to 15 and 16%, respectively.
This correlated with a previously noted increased in oral warts. The 2013-18 cohort was much larger (n=553) with a reduction in prevalence of HPV-32 to 5.2%. Prevalence of HPV-16 dropped to extremely low levels at 0.4% with only two detectible HPV-16 infections in this cohort.